Jade Biosciences (NASDAQ:JBIO) Shares Gap Up – Still a Buy?

Jade Biosciences, Inc. (NASDAQ:JBIO)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $14.39, but opened at $15.31. Jade Biosciences shares last traded at $14.64, with a volume of 10,290 shares traded.

Analysts Set New Price Targets

Several analysts have recently issued reports on JBIO shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Jade Biosciences in a research note on Monday, December 29th. Guggenheim upped their price target on Jade Biosciences from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. HC Wainwright began coverage on Jade Biosciences in a report on Wednesday, January 7th. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Wall Street Zen upgraded Jade Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $20.80.

Jade Biosciences Stock Performance

The firm has a fifty day moving average of $15.03 and a 200-day moving average of $11.06. The stock has a market capitalization of $715.49 million, a price-to-earnings ratio of -1.30 and a beta of 1.02.

Jade Biosciences (NASDAQ:JBIO) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09.

Institutional Trading of Jade Biosciences

Large investors have recently bought and sold shares of the company. Legal & General Group Plc acquired a new position in shares of Jade Biosciences during the second quarter worth $29,000. Russell Investments Group Ltd. purchased a new stake in Jade Biosciences during the 2nd quarter worth $31,000. BNP Paribas Financial Markets purchased a new stake in Jade Biosciences during the 2nd quarter worth $32,000. Ameritas Investment Partners Inc. acquired a new position in Jade Biosciences in the 2nd quarter worth $33,000. Finally, New York State Common Retirement Fund boosted its position in Jade Biosciences by 4,180.3% in the 3rd quarter. New York State Common Retirement Fund now owns 5,222 shares of the company’s stock valued at $45,000 after buying an additional 5,100 shares during the last quarter.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.